Biotech In The 1990s: What's In Store?

The first biotech company--Genentech Inc.--was casually conceived in 1976 by Herbert Boyer, a University of California, San Francisco, biologist, and Robert Swanson, a member of a West Coast venture capital firm, while they were discussing, over a beer, the uses of recombinant DNA technology. Boyer presumably was excited by the prospect that this science could be used to improve the condition of mankind and provide meaningful employ

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The first biotech company--Genentech Inc.--was casually conceived in 1976 by Herbert Boyer, a University of California, San Francisco, biologist, and Robert Swanson, a member of a West Coast venture capital firm, while they were discussing, over a beer, the uses of recombinant DNA technology. Boyer presumably was excited by the prospect that this science could be used to improve the condition of mankind and provide meaningful employment to people.

In 1976, it was not clear how to translate the new technology into its useful roles. But Genentech provided the model for attracting venture capital, reaching agreements with pharmaceutical companies, and securing Wall Street funding. Over the past two decades, this has remained the paradigm for transferring biotechnology advances from university labs to the commercial world.

However, while the Genentech model is still valid overall, the success of biotech companies as we move through the 1990s will depend on how astutely ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Phillip Sharp

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo